Technology
Health
Pharmaceutical

Evelo Biosciences

$8.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.40 (4.99%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell EVLO and other stocks, options, ETFs, and crypto commission-free!

About

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines. Its product candidates are single strains of microbes, selected for defined pharmacological properties. Read More The firm currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Employees
75
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
255.24M
Price-Earnings Ratio
Dividend Yield
Average Volume
75.40K
High Today
$8.62
Low Today
$8.00
Open Price
$8.01
Volume
15.41K
52 Week High
$16.75
52 Week Low
$6.51

Collections

Technology
Health
Pharmaceutical
Medical
Biotechnology
Cancer Prevention
2018 IPO
US

Earnings

-$3.29
-$2.31
-$1.34
-$0.36
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 30, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.